Evidence map›Paper›PMID 23435313›Full record

ArticleExperimental hematology2013

Isolated Hoxa9 overexpression predisposes to the development of lymphoid but not myeloid leukemia.

Sarah H Beachy, Masahiro Onozawa, Deborah Silverman, Yang Jo Chung, Mariela Martinez Rivera, Peter D Aplan

Open access · greenAbstract read
In one paragraph

Article in Experimental hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Underexpression ofFrontiers in oncology · 2022
    Article
  2. MutantCancer research · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sarah H BeachyGenetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Masahiro Onozawa
Deborah Silverman
Yang Jo Chung
Mariela Martinez Rivera
Peter D Aplan
National Cancer Institute · USNational Institutes of Health · US

Funding

Collaborative Pathways that Lead to LeukemiaZIABC010982 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APLAN, PETER · 2009 to 2025
$8.7M
Activation of Proto-Oncogenes by Chromosomal TranslocationZIASC010378 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI APLAN, PETER · 2009 to 2025
$8.4M
Intramural NIH HHS ZIA BC010982Intramural NIH HHS ZIA SC010378
6 · The paper itself

Abstract

Hoxa9 is expressed in hematopoietic stem and progenitor cells, although this expression is usually diminished as these cells undergo differentiation. In addition, aberrant expression of Hoxa9 is strongly associated with both T cell and myeloid leukemia in mice and humans. Despite this strong association, enforced expression of Hoxa9 in murine bone marrow or thymus has only shown a modest ability to transform cells. To investigate this question, we used Vav regulatory elements to generate a transgenic mouse that targets Hoxa9 overexpression to all hematopoietic tissues. High-level expression of the Hoxa9 transgene in the hematopoietic compartment was associated with embryonic lethality, as no pups from founders that expressed high levels of the transgene were born live. However, offspring of an additional founder line, which expressed lower levels of Hoxa9, developed a precursor T cell lymphoblastic leukemia/lymphoma, accompanied by spontaneous Notch1 mutations. In contrast to most murine models of leukemia associated with Hoxa9 overexpression, the Vav-Hoxa9 mice did not overexpress other Hoxa cluster genes, mir196b (a microRNA that is embedded in the Hoxa locus), Meis1, or Pbx3. The Hoxa9 transgenic mouse reported in this study provides a suitable system for the study of Hoxa9 collaborators that drive myeloid and lymphoid malignant transformation.

Indexed as

Genes, HomeoboxAnimalsBone Marrow CellsCells, CulturedCell Transformation, NeoplasticFemaleGene Expression Regulation, LeukemicGene Rearrangement, beta-Chain T-Cell Antigen ReceptorGenes, LethalHematopoietic SystemHomeodomain ProteinsLeukemia, Prolymphocytic, T-CellMaleMiceMice, TransgenicMutationhomeobox protein HOXA9Homeodomain ProteinsHoxA proteinMEIS1 protein, humanMeis1 protein, mouseMyeloid Ecotropic Viral Integration Site 1 ProteinNeoplasm ProteinsNotch1 protein, mouseProto-Oncogene Proteins c-vavReceptor, Notch1Recombinant Fusion Proteins

Identifiers

PMID23435313
PMCPMC3718276
OpenAlexW2043308559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.